Evidence map›Paper›PMID 33162809›Full record

ArticleInternational journal of medical sciences2020

FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.

Yixiao Zhang, Xudong Zhu, Xinbo Qiao, Lisha Sun, Ye Tian, Yongliang Yang, Yuhong Zhao, Caigang Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yixiao ZhangDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
Xudong ZhuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
Xinbo QiaoDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
Lisha SunDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
Ye TianDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
Yongliang YangCenter for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, Liaoning Province, 116023, China.
Yuhong ZhaoDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
Caigang LiuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
China Medical University · CNDalian University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAged, 80 and overAxonemal DyneinsBiomarkers, TumorCarcinoma, Renal CellCell Line, TumorDisease-Free SurvivalFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateKidneyAxonemal DyneinsBiomarkers, TumorFSIP2 protein, humanSeminal Plasma ProteinsccRCCFSIP2predictive biomarkerprognosis

Identifiers

PMID33162809
PMCPMC7645329
OpenAlexW3092377775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.